Monlutenca (Lutetium (177lu) Chloride)

Lutetium (177Lu) chloride, the active ingredient in Monlutenca, is a radiopharmaceutical presented as a sterile solution for clinical use. It is employed in targeted radionuclide therapy to deliver localized radiation to malignant cells. GNH USA supplies Monlutenca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Monlutenca is a radiopharmaceutical used in targeted radionuclide therapy for certain cancer types. - Neuroendocrine tumors: provides targeted beta‑particle radiation to somatostatin‑receptor‑positive lesions. - Prostate cancer (PSMA‑positive): delivers radiation to prostate‑specific membrane antigen expressing cells. - Investigational settings: evaluated in clinical trials for other receptor‑positive malignancies where targeted radiation may be beneficial.

Monlutenca may cause a range of adverse reactions, most of which are related to its radiation properties.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: transient tiredness following administration. - Transient hematologic changes: mild decreases in white blood cells or platelets. - Dry mouth: reduced salivary flow. - Mild renal function changes: temporary elevation of serum creatinine.

Serious or Rare Side Effects: - Severe bone marrow suppression: prolonged neutropenia or thrombocytopenia. - Renal toxicity: significant decline in kidney function. - Radiation‑induced pneumonitis: inflammation of lung tissue. - Secondary malignancies: rare risk of new cancer development due to radiation exposure.

Monlutenca requires careful handling and patient monitoring. - Renal function assessment: evaluate baseline creatinine and glomerular filtration rate. - Hematologic monitoring: perform complete blood counts before and after therapy. - Pregnancy avoidance: contraindicated in pregnant patients; verify status before use. - Breastfeeding restriction: advise cessation of nursing during and after treatment. - Concomitant nephrotoxic drugs: avoid or adjust dosing of agents that may impair kidney function. - Store at ambient temperature: keep in original container, protect from light and moisture.

Monlutenca can interact with other agents that affect renal or hematologic health.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may increase cumulative radiation dose. - Nephrotoxic chemotherapy (e.g., cisplatin): heightened risk of renal injury. - Myelosuppressive agents (e.g., high‑dose methotrexate): severe bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal parameters closely. - Anticoagulants: watch for bleeding if severe thrombocytopenia occurs. - Diuretics: adjust fluid balance to support kidney clearance.